Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruxolitinib - Incyte Corporation/Novartis

Drug Profile

Ruxolitinib - Incyte Corporation/Novartis

Alternative Names: INC-424; INCB 018424 phosphate; INCB-018424; INCB-18424; Jakabi; Jakafi; Jakavi; Opzelura; RUX; ruxolitinib phosphate

Latest Information Update: 08 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Baylor Breast Care Center; Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Lymphoma Academic Research Organisation; Novartis; RWTH Aachen University; University Health Network of Toronto; University of Cologne; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antianaemics; Antibronchitics; Antihaemorrhagics; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Cyclopentanes; Nitriles; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Pancreatic cancer; Polycythaemia vera; Essential thrombocythaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis; Graft-versus-host disease; Myelofibrosis; Polycythaemia vera
  • Phase III Cytokine release syndrome; Essential thrombocythaemia; SARS-CoV-2 acute respiratory disease; Vitiligo
  • Phase II/III COVID-19 pneumonia
  • Phase II Acute myeloid leukaemia; Alopecia areata; Breast cancer; Breast disorders; Bronchiolitis obliterans; Cachexia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Head and neck cancer; Hodgkin's disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Thalassaemia
  • Phase I/II Multiple myeloma
  • No development reported Psoriasis
  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 06 Oct 2021 Biomarkers information updated
  • 02 Oct 2021 Pooled efficacy and safety data from the TRuE-V clinical trial program (TRuE-V1 and TRuE-V2) in Vitiligo released by Incyte Corporation
  • 23 Sep 2021 Launched for Atopic dermatitis (In adolescents, In children, In adults) in USA (Topical)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top